Sanner Appoints Stefan Verheyden CEO
Heino Lennartz will take over the role on an interim basis until Verheyden takes office in fall 2025.
As part of its strategic focus on the CDMO sector, the Sanner Group is now drawing even more specifically on expertise from the pharmaceutical industry - both in operations and at the management level. Accordingly, CEO Johannis Willem van Vliet will be leaving the company at short notice.
Heino Lennartz will assume the role of CEO on an interim basis until the new CEO takes office in fall 2025. Heino Lennartz has extensive knowledge of the pharmaceutical and CDMO sectors and, as Chairman, is already very familiar with the processes and activities of the Sanner Group. He will be responsible for the management of the company on an interim basis and will support the future CEO during the handover.
The new CEO will be Stefan Verheyden. A chemist by training, he has been working in the pharma and biopharma industry for over 30 years and also has extensive experience in the primary packaging sector. He joins Sanner from Gerresheimer and previously worked at Avantor, Thermo Fisher and VWR, among others.
"We are delighted to welcome Mr. Verheyden, such an experienced CEO, to the Sanner Group. His many years of expertise and his reputation in the industry will be of great benefit to us in both the packaging and CDMO sectors," says Heino Lennartz.
"We would like to thank Johannis Willem van Vliet for his commitment and significant contributions at an important stage of our company," says Lennartz. "He has taken decisive steps to position the Sanner Group as a global medtech and pharma supplier. This includes in particular the acquisitions of Springboard and Gilero as well as the successful commissioning of our new production sites in Bensheim and Greensboro."
